Weekend update, future ahead Has been a while. Family crisis. Our son died not long ago.
Life is not supposed to happen thst way. Saying that, very unpleasant time of our life right now.
Regarding ONC ? I stated previously my timeline for any outcome is almost unlimited.
understanding if Pelareorep has proven efficacy & co- therapy value, then Onc will be worth many multiples if it's existing trading price.
The Q2 upcoming presentation, will most likely be a bit different.
New CEO, new persona & perhaps different discussions.
Factually, they have announced O.S. Numbers will be reported second half oF this year.
being anytime between now & Dec 31.
They have a new business development VP. Lots of focus on the business side.
Afterall, with the in- place trials & planned future trials, they are much much closer to being a good opportunity for a larger pharma company to acquire.
The FDA type C meeting did provide favourable directions for the MBc cancer phase 3 ( they are calling it a licence enabling study.
likewise for the pancreatic cancer trial, hoasted & lead by CGAR.
recall, that is a cotherapy with Roche.
i also mentioned it has been wayyyyyy too long in the process.
mutiple reasons.
most recent & very significant, the cancellation of the PanCan precision promise opportunity.
Onc did recover from that & shift gears over to CGAR.
however , more delays.
My best intuitive read oF the whole story, from a Birds Eye view?
Any negotiations, will be contingent on the O.S. Numbers from bracelet.
Good news, which is expected elevates the value significantly.
bad news, moves Onc down to a single known opportunity being the pancreatitc cancer.
granted there are smaller things ongoing. Being the imuotherapy potential, CAR-T , etc.
smaller less discussed, but still opportunities.
For the big bucks, they need to be bought out, or a significant licensing agreement.
The bracelet O.S. Numbers will provide solid negotiation evidence.
My prediction?
after the Q2 meeting, there will be a flurry of activity.
Tye SP has been intentionally supported. Very low volume. Any glimmer of excitement will move the needle upwards.
Many analysts will be looking for guidance from the new CEO.
clinically, we know more or less all there is to know for now.
The FDA has given fast track designation for both panc & MBc cancer treatments.
biggest mystery is how/ which pharma will partner with the MBc
again, bring on the O.S. Reults.
A little knowledge based tidbit.....the longer the O.S. Numbers take the better it looks for Pela & ONC.
Biotechs are gambles. Junior even more so.
You have an opportunity, with some vision. The obvious is O.S. Is longer than expected.
That is public information. Few understand that.
imho, a well worth the risk gamble at this point.
As has been pointed out. Other development pharma companies have been bought out , offering a lot less than Onc.
Why no deal yet?
Good O.S, numbers adds huge value to Onc.
mangement knows what to expect.
so they are not giving the company away, just to be faster.
sharholder value is not about the trading price. It is about the value of the company should Pela get to market.
like I said multiples of existing trading.
The day traders are mostly long gone.
Have a great weekend all. Be safe & healthy.